[A new drug for macular degeneration. A breakthrough accomplished (interview by Waldtraud Paukstadt)].
Holz
Frank G
FG
D020533:Angiogenesis Inhibitors / Q000191:economics / Q000627:therapeutic use*; D000911:Antibodies, Monoclonal / Q000191:economics / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide / Q000191:economics / Q000627:therapeutic use; D000068258:Bevacizumab; D016527:Drug Costs; D005858:Germany; D006801:Humans; D008268:Macular Degeneration / Q000188:drug therapy* / Q000191:economics; D000069579:Ranibizumab; D016896:Treatment Outcome
D020533:Angiogenesis Inhibitors; D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D052157:Aptamers, Nucleotide; C495058:pegaptanib; D000068258:Bevacizumab; D000069579:Ranibizumab